Fast US shipping - at your door in 5-7 days/
The best prices online - go ahead and compare/
Reference-grade · >99% HPLC verified purity/
COA on every batch - mass-spec confirmed/
Pay with BTC · ETH · USDC - 10% off crypto orders/
VANTA
//Research Overview

Semax: A Research Reference on the ACTH(4-10) Analog Peptide

Semax is a synthetic heptapeptide derived from a fragment of adrenocorticotropic hormone (ACTH) that has been examined extensively in preclinical neuroscience literature. This page summarizes what the peptide is, the mechanisms researchers have studied, and the laboratory models in which it appears. All information is provided for research and reference purposes only and describes published findings in animal and in-vitro systems, not outcomes in humans.

VANTA Research Desk · Updated 2026-06-19

All products are sold strictly for laboratory research purposes only. Not for human consumption, diagnostic, or therapeutic use.

What is Semax?

Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro, structurally based on the ACTH(4-7) fragment extended with a C-terminal Pro-Gly-Pro tripeptide. In the literature it is described as an analog of the N-terminal adrenocorticotropic hormone fragment 4-10 that lacks the classic hormonal (corticotropic) activity of the parent molecule. The Pro-Gly-Pro motif is generally described as a stabilizing addition that researchers associate with greater resistance to enzymatic degradation in experimental preparations.

Within research contexts, Semax is categorized as a melanocortin-derived (ACTH-fragment) peptide and is frequently grouped with so-called regulatory or "nootropic" peptides in published Russian and international literature. It is supplied by VANTA strictly as a reference compound for in-vitro and laboratory research use only.

Studied mechanisms

A recurring theme in the Semax literature is its association with the neurotrophin system. Preclinical work by Dolotov and colleagues reported that the heptapeptide stimulated brain-derived neurotrophic factor (BDNF) expression across several regions of the rat brain in vivo, and a 2006 Brain Research study described Semax modulating BDNF protein and trkB receptor activation in the rat hippocampus.

Other mechanistic investigations have examined Semax in relation to nerve growth factor (NGF) and BDNF gene expression dynamics, intracellular signaling pathway genes, and monoaminergic systems. Some reports characterize the peptide as an MC4-receptor antagonist that lacks corticotropic hormonal activity. These descriptions reflect mechanisms observed in animal and cell-based research models and are reported here only as published scientific observations.

Research models and findings (hedged)

Semax has been studied across a range of preclinical paradigms. Researchers have examined it in rodent models of cerebral ischemia and ischemia-reperfusion, where genome-wide transcriptional analyses reported changes in genes associated with neurotrophins, immune response, and vascular systems. A proteomic study published in 2021 characterized brain protein expression profiles in a rat model of cerebral ischemia-reperfusion under Semax exposure.

Additional animal-model literature has investigated the peptide in the context of MPTP-induced lesions of the dopaminergic system, basal forebrain cholinergic neuron survival in vitro, and nitric-oxide generation following experimental global ischemia. These are descriptions of findings in laboratory and animal systems. They are not statements about safety, efficacy, or outcomes in humans, and nothing here should be read as guidance for use in people.

Why researchers reference ACTH-fragment peptides

ACTH(4-10)-derived peptides such as Semax are of interest to investigators studying neuropeptide signaling because they allow examination of melanocortin-related pathways while reportedly being dissociated from the steroidogenic hormonal axis. Published reviews have summarized decades of design and characterization work on the molecule and its derivatives, including a long-running body of work describing it as a model regulatory peptide.

For laboratory researchers, this makes Semax a frequently cited reference compound when designing experiments around BDNF/trkB signaling, neurotrophin gene expression, and melanocortin-receptor pharmacology in animal and in-vitro systems. VANTA provides the compound to support that kind of controlled, reference-grade experimentation only.

How VANTA verifies Semax

Every Semax lot VANTA supplies is intended as a reference-grade research material, and identity and purity are documented before release. Purity is assessed by reversed-phase high-performance liquid chromatography (HPLC), and peptide identity is confirmed by mass spectrometry to verify the expected molecular mass of the Met-Glu-His-Phe-Pro-Gly-Pro sequence.

Each batch ships with a per-batch Certificate of Analysis (COA) that records the analytical results for that specific lot, so researchers can document chain-of-evidence for the material used in their work. This verification workflow is provided so laboratories can confirm what they are working with. It is not a representation of suitability for any use in humans or animals; Semax from VANTA is sold for laboratory research use only.

References

  1. 1.Dolotov et al. (2003), Dokl Biol Sci - SEMAX stimulates BDNF expression in different areas of the rat brain in vivo
  2. 2.Dolotov et al. (2006), Brain Research - Semax regulates BDNF and trkB expression in the rat hippocampus
  3. 3.Medvedeva et al. (2014) - Semax affects expression of immune- and vascular-system genes in rat brain focal ischemia (genome-wide analysis)
  4. 4.Brain protein expression profile confirms the protective effect of the ACTH(4-7)PGP peptide (Semax) in a rat model of cerebral ischemia-reperfusion (2021)
  5. 5.Neuroprotective effects of Semax in MPTP-induced lesions of the brain dopaminergic system (rat model)
  6. 6.Nootropic ACTH(4-10) analog Semax - review of 15 years of design and study